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For some neurodegenerative disorders, particularly those such as Parkinson’s disease which 
have a relatively selective loss of a specific cell type (dopaminergic neurons) from a relatively 
focal region, cell therapies offer a possible means of replacing or protecting the dying neurons. 
Replacing the lost neurons by transplanting fetal ventral mesencephalic tissue into the 
striatum has shown clinical benefit,[1] but some quite long-standing challenges still need to be 
resolved, particularly graft survival,[2] as typically only 5-10% of the dopaminergic neurons 
survive the transplantation process.[3]  
Improving cell survival post transplantation to the brain is a research topic that has received 
much attention, with studies analyzing anti-caspase therapeutics, tropic support, gene delivery 
to the host site, and co-transplantation of supporting cells etc.[4] These studies have resulted in 
limited success. In addition, a more recent approach of using materials such as soft hydrogels 
that gel in situ (in vivo) also showed only incremental improvements in cell survival.[5, 6] 
Whilst the host immune system clearly plays a significant role in determining the fate of the 
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graft,[7, 8] there is mounting evidence that providing cells with a substrate on which to adhere 
prior to transplantation into the brain can lead to an increase in cell survival.[9-11] Anoikis 
(Greek meaning: without a home [12]), is the process by which cells die through lack of 
attachment, and has been proposed as a major factor contributing to cell death post-
transplantation in the CNS.[13] The process of using an in situ forming gel may affect the host 
response to the graft, [6] but would not ameliorate the problem of anoikis as cells are added in 
a trypsinized state to the hydrogel precursor components. In contrast, microscale spherical 
poly-L-lysine coated glass beads have been used to culture cells on the surface prior to 
transplantation.[11] Such a simple transplantation method produced a change in hippocampal 
neuron survival from reporting no surviving cells in the control group compared to a 76% cell 
survival when transplanted on glass beads. Such beads provided no barrier to the host 
response, no trophic support, and the animals received no immuno-suppression, thus showing 
it could be anoikis that was ameliorated by the provision an adherent surface throughout the 
transplantation procedure.  
Such studies provide a solid rationale for the development of a more suitable material to 
which cells can adhere and differentiate, prior to implantation. For clinical application in the 
majority of CNS regions (excluding the spinal cord where macroscale scaffolds can be 
implanted [14])) the scaffold material should be injectable[15]. This means that the dimensions 
of the material must either be smaller than the inner diameter of the injection cannula/needle, 
or the material must be collapsible and mechanically tough, in order to withstand large 
deformation within the needle without losing integrity, and must re-expand to the original 
shape post injection. Recently, cryogelation technology was successfully applied for the 
preparation of macroporous hydrogel (cryogel) scaffolds.[16-18] Cryogels are formed from the 
aqueous reaction mixture at sub-zero temperature using the process of ice crystal formation 
for structuring during the gelation process (Scheme 1) and subsequent lyophilization or 
melting of the ice crystal porogens renders a scaffold with a sponge-like structure. Due to 
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cryoconcentration, the non-frozen liquid regions taking part in gelation contain highly 
concentrated precursor molecules, resulting in cryogel struts which feature a higher stiffness 
compared to the corresponding bulk hydrogel materials.[19] Furthermore, cryogels can 
withstand high compressive stress at high strains without destroying the gel matrix.[16] [17] [19] 
The aim of this study was to use a recently developed biohybrid hydrogel material consisting 
of star-shaped poly(ethylene glycol) (starPEG) and heparin that already has proven 
biocompatibility in the brain[20] to construct cryogel microcarriers for cell adherence/growth. 
We hypothesized that by using a combination of an emulsion technique with cryogelation, 
micron scale cryogel particles (microcarriers) could be produced which can bind growth 
factors, and allow cell growth in the interconnected macropores to protect them during 
injection through a small bore needle.  
Cryogel microcarriers were synthesized via EDC/sulfo-NHS mediated crosslinking of amino 
terminated starPEG and Alexa 647 labeled heparin (Scheme 1a). After activating the 
carboxylic acid groups of the heparin, the crosslinking reaction took place in a water-in-oil 
emulsion. Therefore, small droplets of the hydrogel reaction mixture were formed in an 
organic phase by rapid stirring (end goal was to fit through a 27 gauge needle). The reaction 
vessel was then submerged in an ethanol bath at -20°C to facilitate ice crystal formation in the 
gelling mixture (Scheme 1b). Lyophilization removed both the surrounding organic solvent 
and the ice crystals from the gel matrix, to leave macroporous microcarriers ready for 
subsequent characterization and study.  
SEM analysis of the dry cryogel microcarriers revealed that the microcarriers generally have a 
spherical form with a highly porous structure (Figure 1a). The pores are interconnected and 
could also be clearly seen present in the swollen wet state of the cryogel via CLSM (Figure 
1b). During the transition from a dry state to a wet state, the cryogel microcarriers swell an 
average of 2.1 times in diameter, and 8.8 times in volume, which could be observed and 
calculated by light microscopy (see Supporting Information Figure S1a). The average 
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diameter of the cryogel microcarriers is 299 µm (Figure S1b) which is larger than the inner 
bore of a cannula typically used for transplanting cells into the brain (between 27-30 gauge, or 
160 – 210 µm inner diameter).[6, 21] However, the spongy materials exhibit irregular 
macropores with an average size of 72 µm (Figure S1c), separated by struts of only about 10 
µm in width, and a high porosity, indicating plenty of spaces for collapse. 
It is likely that anoikis is a large contributor to the vast cell death post transplantation to the 
brain; however, research groups have also investigated the idea of delivering neurotrophic 
factors such as glial cell line-derived neurotrophic factor (GDNF) to the graft with the aim of 
improving survival. For example, poly(lactic-co-glycolic acid) (PLGA) spheres were used to 
deliver GDNF to the striatum during grafting of ventral mesencephalic (VM) tissue, but little 
beneficial effect was observed [22]. The same group then coated the PLGA spheres with poly-
L-lysine and prior cultured the VM cells on the spheres before transplantation. A vast increase
in cell survival was observed for cells transplanted on spheres either with or without 
encapsulated GDNF,[10] showing that prior adherence is clearly important. We were attracted 
by the idea of providing a cell adherent microcarrier, which can also deliver growth factors to 
the transplant site, not just for graft survival but more for host neuroprotection. In this study 
we investigated GDNF and NGF for their neuroprotective properties.[23] These growth factors 
were loaded to the microcarriers by electrostatic interaction between the proteins and the 
heparin[20] within the cryogel microcarrier structure. Both GDNF and nerve growth factor 
(NGF) could be loaded onto the cryogel microcarriers at three different concentrations of 
loading solutions: 50, 100 and 500 ng/mL (see Supporting Information Figure S2 and S3). 
These three different concentrations gave distinctly different release rates of the growth 
factors into the surrounding medium, whereby the cryogels loaded with the most growth 
factor released the most growth factor over the seven day period (Figure 1c, Figure S2b and 
Figure S3b). Interestingly, it appears that NGF has a slightly greater affinity for the cryogel 
microcarriers as observed by the higher percentage loading and lower NGF release over the 
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seven day period than GDNF, which appeared saturated at the highest concentration, and 
showed a higher release rate.  
Many spherical microparticles designed to deliver growth factors do so with an initial burst 
release, with the majority of the growth factor released over the first day or two.[22-24] Indeed 
poor release kinetics is still a hurdle for local growth factor delivery in the CNS.[23] In contrast, 
although the cryogel microcarriers are spherical in overall shape, the surface area of the 
cryogel struts (to which the growth factor is bound) is very different from that of a regular 
sphere. Furthermore, the highly negative charge of heparin allows for strong binding with 
growth factors such as GDNF[25]. For example, PLGA spheres formed in emulsion,[9, 26] or 
collagen spheres formed from a sacrificial template,[27] consist of a shell of a surface area as 
opposed to the cryogel microcarriers which contain interconnected pores that reach right to 
the center of the particle. 
Several cell types have been proposed for transplantation to the brain for restorative therapy 
of diseases such as Parkinson’s disease.[28] Within this study, we were focusing on bone 
marrow derived stem cells (MSCs) as they have been proposed not only for restorative 
therapy, but also for neuroprotective applications in the Parkinsonian brain as they can be 
readily transfected to over-express GDNF.[29] However, despite promising rescue of 
dopaminergic neurons from neurotoxic insult in the vicinity of the graft,[29] the poor survival 
of these cells in vivo limits their therapeutic potential.[30] As a second cell type, the “neuron-
like” cell PC12 cells were used in this study. To analyze the ability of MSCs and PC12 cells 
to attach and grow on the cryogel microcarriers, a spinner flask was used, whereby either cell 
type was added with the cryogel microcarriers into the spinner flask and stirred at 30 rpm with 
an on/off interval cycle of two minutes stirring, 30 minutes still, for the desired cultivation 
time (3 or 7 days). This culture protocol, often used for culturing cells on microcarrier 
materials,[31] allowed for both cell types to attach to the cryogel microcarriers. Figure 1d 
shows a CLSM image of green fluorescent protein (GFP) fluorescent MSCs growing on a 
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cryogel microcarrier after three days in culture (also see Figure S4a and b and Figure S8 for 
quantification of loading). When observing a thin section through the cross section of a 
cryogel microcarrier, the cells can typically be seen to be adherent to the outer edge of the 
sphere (Figure S2a and b), as this would be the first region the cell would contact during 
spinner flask cultivation. PC12 cells were cultivated for a longer time period (7 days) as it was 
desired to see if they could produce neurites on the cryogel microcarriers in the presence of 
NGF, which typically take an extended time to form.[24] Figure 1e and f show CLSM images 
of PC12 cells grown in the presence of medium containing 500 ng/mL of NGF (non-
differentiated PC12 cells can be seen in Figure S4c and d). For the NGF differentiated 
sample small neurites (Figure 1e) can typically be observed by βIII tubulin staining, 
indicating that these cryogel microcarriers can support neuron growth prior to transplantation. 
In this way, it could be envisaged that neurons or iPS cell derived neurons could be allowed to 
differentiate, or partially differentiate as required, prior to transplantation without any 
trypsinization or axon damage prior to transplantation.  
Interestingly we observed that when MSCs or PC12 cells were cultured on tissue culture 
plastic, or poly-L-lysine coated tissue culture plastic respectively, 24 hours after adherence 
both cell types partially migrated onto the empty (no cells or growth factor) cryogel 
microcarriers placed on top of them in the well. This could be quantified studying the cell 
metabolic activity after removal of the microcarriers, in comparison to untreated cells as the 
control group (Figure 2a and b). However, CLSM of the MSCs (Figure 2c) and light 
microscopy of the PC12 cells (Figure 2d) prior to the separation of the microcarriers from the 
original cell seeded well revealed that many cryogel microcarriers contained cells despite 
being originally added as empty cryogel microcarriers. Light microscopy revealed that with 
increasing concentration of cryogel microcarriers large clear patches could be seen on the well 
bottom, devoid of PC12 cells, whilst distinct cell aggregates appeared on the cryogel 
microcarriers (Figure S5). Figure 2b shows that after three days over 50% of the PC12 cells 
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had migrated onto the cryogel microcarriers at a concentration of 20 mg/mL (the highest 
concentration of microcarriers analyzed –almost a complete covering of the well bottom). The 
MSC migration was more varied (Figure 2a), however at all concentrations many cryogel 
microcarriers could be visualized to contain the GFP positive stem cells. For some 
applications, such as ex vivo gene delivery to the brain, integration of the grafted tissue is not 
important. For instance, in some clinical trials, integration has been purposefully avoided by 
the use of a protective encapsulating device to separate the transplanted tissue from the host 
cells and immune response, but still allow release of the cell secreted growth factor.[32] 
However, for cell replacement therapy, such as with fetal dopaminergic neurons, graft 
survival and correct integration is of utmost importance for a functional benefit of the 
transplant, and remains a key research topic.[33]  
Poly-L-lysine coated glass beads provide a stiff surface for cell adhesion and migration [11], 
but cannot be compressed upon injection so contain a large dead space and therefore limit the 
number of cells that can be transplanted.[34] In contrast, the microcarrier system developed 
herein provides cells with locally stiff struts [19] on which to adhere, yet allows a collapsible 
sponge-like structure for brain injection. Biomaterials designed for assisting cell 
transplantation or drug delivery to the majority of the brain regions must be injectable (except 
peripheral cortical regions [35]), and, for minimal damage to surrounding tissue, fine gauge 
needles/cannula are often used.[7, 36] Recently, neuronal networks have been formed on 
cryogel scaffolds, by seeding SHSY5Y cells or primary neurons on a preformed alginate and 
carboxymethyl-cellulose macroscale cryogel.[18] Although cell survival was shown after 
injection of these scaffolds in vitro, a 16 gauge needle was required. This large gauge (needle 
outer diameter of 1.65mm) severely limits the analysis of such macroscale scaffolds in the 
midbrain of small rodents (for example the cross sectional mediolateral width of the striatum 
is typically around 3.3mm for 200-250 gram adult Sprague Dawley rats [27]) as it would cause 
too much tissue disruption. For future cell transplantation applications in Parkinson’s disease 
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models we wanted to analyze if the cryogel microcarriers could fit through a 27 gauge needle 
(inner diameter 0.22 mm, outer diameter 0.41mm) and yet maintain cell viability. Figure 2e 
shows the cell viability after the injection of microcarriers seeded either with rMSCs or PC12 
cells, either using no needle (control group) or using a 27 gauge needle. The cryogel can 
collapse and reform outside the needle without affecting the overall shape of the microcarrier, 
and Figure 2f shows a sequence of images taken as cryogel microcarriers pass unaffected 
through the needle. No resistance was felt to injection, and after a several injections of 
unloaded microcarriers, no damage or small fragments could be observed. This is 
underpinned by the long plateau region in the uniaxial compression stress-strain curves of the 
corresponding bulk cryogel materials (Figure S6 and References [17, 19]), demonstrating that 
the sponge-like materials are able to adsorb large amounts of energy without experiencing a 
large increase in stress. Consequently, these rather soft materials are very tough and do not 
even break at a compression strain of over 90%.   
In conclusion, microscale macroporous hydrogels could be prepared using a water-in-oil 
emulsion and by allowing the subsequent gelation to occur in the aqueous phase at -20oC 
(cryogelation) and were hence termed cryogel microcarriers. These microcarriers could be 
functionalized with two different growth factors loaded with both MSCs and PC12 cells. Due 
to their spongy structure and their dense pore walls, that provide structural support to the 
highly porous materials, the cell loaded cryogel microcarriers could be injected through a 27 
gauge needle without destruction and without loss of the cell viability. Moreover, it was 
shown that both cell types could migrate from the well plate onto the microcarriers suggesting 
that they will not hinder graft integration in the brain. Finally, the near zero order release 
profile of growth factors suggest that the cryogel microcarriers could be used for a 
combination therapy for neurodegenerative disorders. Future studies will assess whether the 
cryogel microcarriers can improve the survival of fetal ventral mesencephalic cells after 
9 
transplantation into the parkinsonian rat brain, where injection through a small bore cannula 
without backpressure or clogging will be vital. 
Experimental Section  
Cryogel Microcarrier Preparation: 
The cryogels were prepared by crosslinking the amino end-functionalized starPEG with 
EDC/sulfo-NHS-activated carboxylic acid groups of heparin at -20°C. 200 µl of hydrogel 
mixture was prepared with a molar ratio of starPEG to heparin of 1:1 (11.11 mg and 15.56 mg 
respectively) and a ratio of EDC to sulfo-NHS of 2:1 (1.7 mg and 0.97 mg respectively). 
Therefore, heparin, starPEG, EDC and sulfo-NHS were dissolved separately in deionized, 
decarbonized water (MilliQ) using an ultrasonic bath filled with ice-cooled water for 
approximately 3–5 minutes, and afterwards all solutions were kept on ice. A two-fold molar 
excess of EDC to NH2-groups of starPEG was used and added with the sulfo-NHS solution to 
the heparin. After vortexing (Minishaker MS2, IKA, Germany) and 15 minutes incubation on 
ice (to activate the heparin carboxylic groups) the starPEG solution was added and the 
mixture was further vortexed for 15 seconds. 
A water-in-oil emulsion was used to create macroporous particles of the hydrogel. 200 µl of 
the hydrogel reaction mixture was added to 4 ml of toluene (the non-solvent medium 
containing Synperonic PEP105 as a stabilizing agent). The two-phase system was stirred (600 
rpm) at room temperature for 13 minutes to form droplets. However, after 12 min, 1 ml of a 
higher concentrated Synperonic solution (20 mg/ml) was additionally added to prevent droplet 
agglomeration. The dispersion was chilled to -20°C with an ethanol bath cooled by an 
immersion cooling unit (TC 100E-F-NR, Huber, Germany). The frozen droplets were stirred 
for two hours at -20°C, before they were allowed to settle and remain overnight at -20°C . The 
microspheres were lyophilized overnight to remove the toluene and ice crystals. The 
microcarriers were washed three times with ethanol and two times with PBS.  
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Stem Cell Loading Studies: 
Mesenchymal stem cells (MSCs) extracted from a GFP transgenic rat [30] were a kind gift 
from Dr. Linda Howard, National University of Ireland Galway, Ireland. They were cultured 
in a half/half mix of Minimum Essential Medium Eagle Alpha Modification (α MEM) and 
F12 media, supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin 
(P/S) and incubated at 37°C in 5% CO2 at 90% humidity. For loading cells to the cryogel 
microcarriers, a spinner flask method was used, whereby the spin rate and the interval 
between spin and non-spin cycles can be controlled. The spinner flasks (glass, for a 25 ml 
volume, Chemglass Life Sciences, Germany) were first coated with Sigmacote® (Sigma, to 
reduce cell adhesion to the glass walls), and allowed to dry before autoclave sterilization. A 
mass of the cryogel microcarriers was obtained in the semi-swollen by weighing them out into 
a 40 µm pores size well insert filter with excess liquid removed. A ratio of 50 mg semi-dry 
microcarriers per 1 million cells was kept constant throughout the experiments. The cryogel 
microcarriers were firstly re-hydrated with PBS containing 0.1% ProClin300 (Sigma) and left 
overnight for sterilization. After washing (three times) with sterile PBS, the cryogel 
microcarriers were then re-suspended in the same media used for culturing the MSCs and then 
added to the spinner flask. 1 million cells were then obtained by trypsinization from the 
culture flask, suspended in fresh media, and added to the spinner flask, to make a total volume 
of 25 ml. This was then placed in the incubator on top of a Variomag Biomodul 40B 
controlled magnetic stirrer (H + P Labortechnik GmbH), and set to a spin cycle of 30 rpm for 
2 minutes with 30 minutes interval between spin cycles. After the desired incubation time, the 
cell loaded cryogel microcarriers were removed and again filtered to remove the excess media, 
before being processed for further study (e.g. fixation, microscopy etc). 
PC12 Cell Loading: 
PC12 cells were cultured in Dulbecco’s Modified Eagle's medium (DMEM) GlutaMax 
supplemented with 5 % fetal bovine serum (FBS), 5% horse serum and 1% 
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penicillin/streptomycin (P/S) and incubated at 37°C in 5% CO2 at 90% humidity. Cells were 
loaded to the microcarriers using the spinner flask method described above for the stem cells. 
However, this was performed either in the presence or absence of NGF in the media (500 
ng/mL). Cells were visualized by CLSM after βIII tubulin staining using a 
immunocytochemistry protocol adapted from Kraskiewicz et al.,[24] but with a 3 µm pore cell 
culture insert for easy separation of cryogel microcarriers from the sollutions. 
Effect of Injection on Microcarrier Shape and Cell Viability: 
20,000 cells per mg of cryogel microcarrier were loaded as described earlier. After three days 
of cultivation at 37°C in 5% CO2 at 90% humidity, 100 µl of the microcarrier media 
suspension was injected into a 96 well plate via a sterile 1 ml syringe at a rate of 
approximately 1000 µl per minute (as used by Aguado et al., [37]) . The injection was carried 
out with or without a 27 gauge needle. After three hours of incubation following the injection 
process, the percentage of cell survival was analyzed using PrestoBlue®  (a Resazurin-based 
assay) , normalized to cells injected via the syringe without a needle (negative control). 
Resazurin-based assays can be used to measure cell viability via the metabolic activity of the 
cells. PrestoBlue® (10 µL) was simple added to the 100 µL of cell loaded microcarriers that 
had either passed through the syringe and needle (test group) or just pushed out of the syringe 
(control group). After an incubation time of 30 minutes (37°C in 5% CO2 at 90% humidity) 
the supernatant was removed and the fluorescence intensity was measured using a Tecan 
multiwell plate reader according to the manufacturer´s protocol.  
Statistical Analysis: 
A student T-test was used for comparison of the cell survival during the injection procedure 
with and without a needle, (P ≤ 0.05) using GraphPad Prism software. 
Supporting Information  
12 
Supporting Information, including materials, cryogel microcarrier characterization, growth 
factor loading and release, and cell migration analysis is available from the Wiley Online 
Library or from the author. 
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Scheme 1. A schematic diagram depicting the synthesis and cell loading of the cryogel 
microcarriers. (a) StarPEG and heparin are crosslinked via EDC/sNHS chemistry in droplets 
of the aqueous reaction mixture in a non-solvent medium containing a stabilizing agent. (b) 
Freezing the gelling solution followed by lyophilization gives rise to the macroporous 
structure. (c) Cells can be cultivated on the cryogel microcarriers using a spinner flask culture 
method.  
15 
Figure 1. Cryogel characterization and cell growth. SEM image of the dry microcarrier (a) 
(and high magnification insert, scale bar: 20 µm) and CLSM fluorescence image (b) of Alexa 
647 labeled PBS swollen cryogel microcarriers (red). (c) GDNF released into the media from 
the microcarriers is dependent on the initial loading concentration. Representative CLSM 
images of GFP positive mesenchymal stem cell (green) (d) or small neurites projecting from 
βIII tubulin stained PC12 cells (green) (e) and f)) cultured on the cryogel microcarriers for 
seven days.   
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Figure 2. Cryogel microcarriers allow cell migration and injection through a 27 gauge needle. 
Quantification of rMSC migration (a) and PC12 migration (b) onto the cryogel microcarriers 
as a function of microcarrier concentration, as observed by CLSM for GFP positive MSCs (c) 
and light microscopy for PC12 cells (pseudo colored for clarity) (d). Injection of cryogels 
through a 27 gauge needle was shown to have no effect on cell survival (e) (n=4, no 
statistically significant difference between groups, student T-test (P ≤ 0.05) and could be 
visualized by light microscopy (see also Figure S7) (f)  
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